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SUPPLEMENTARY NOTES
ABSTRACT
Increasing evidence suggests that many types of ovarian cancers originate within the fallopian tube. The scope of this Translational Partnership project is to define a unique premalignant gene expression profile and to identify causal epigenetic relationships. As outlined in the statement of work, our analyses have identified a premalignant expression signature which potentially reflects early steps in ovarian carcinogenesis. While genes differentially expressed in BRCA1 normal Fallopian Tube epithelia and BRCA1 ovarian carcinoma were investigated in the Swisher lab, we have further established the proof-of-principle that demonstrates the role of DNA methylation of CTCF binding sites in cancer tissues. We gathered evidence that genes that are part of the premalignant signature are differentially methylated in ovarian cancer cell lines. We have begun to isolate and pool samples by laser-capture microscopy. In the coming year, we will perform extensive mapping of DNA methylation to precisely determine epigenetic changes that affect the normal expression of genes in ovarian cancer. References……………………………………………………………………………. 6
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INTRODUCTION
The development of novel strategies and treatment methods for ovarian cancer, the most lethal of gynecological cancers, has been hindered by the lack of understanding of the biology of malignant transformation in the ovary. Previous evidence led to the hypothesis that many ovarian cancers originate within the fallopian tube.
However, the precise mechanism of aberrant gene expression profiles remained unknown. In the first half of this funded 2-year project, Dr. Swisher's lab has identified candidate genes that may contribute to early carcinogenesis using fallopian tube tissue from women with BRCA1 mutations. To identify the underlying cause and mechanism for deregulated expression of this subset of genes, we initiated experiments to define the epigenetic status of this gene set. In the first year we established experimental approaches capable of identifying differential methylation patterns at specific gene loci using small cell/tissue samples similar to those that are derived from laser capture microscopy (LCM).
BODY
Comparison of gene expression in normal and cancerous tubal epithelia from both BRCA1 mutation carriers and control groups revealed a surprisingly low number of deregulated gene loci. In total, 41 concordant overlapping probe sets identified 29 genes which were upregulated and 12 which were downregulated. Previous work in several labs including ours has revealed that epigenetic aberrations including methylation of CTCF target sites are an early and key event in carcinogenesis [ [1] , reviewed in [2] ]. CpG methylation of CTCF target motifs inhibits binding of CTCF and permits spreading of DNA methylation and subsequent silencing of genes such as tumor suppressor genes [3] . While gene profiling studies in laser captured cells were ongoing in year one, we tested this model at the HOX gene locus in cancer cell lines established from ovarian, breast and prostate tissue. The HOXA gene cluster is a family of homeotic genes that encode transcription factors which are frequently inactivated in cancer cell types. The HOX gene domain contains several CTCF sites (hx1-hx5) previously identified in our ChIP-Chip in the breast epithelial cell line HBL100. Importantly, CTCF binding at hx1 is absent in the prostate epithelial cell line PC3 [4] . Genomic sequencing of the hx1 region revealed complete sequence identity at this site in HBL100 and PC3 cells, suggesting that epigenetic mechanisms account for the loss of CTCF binding in PC3 prostate cancer cells. Using a combination of methylation-sensitive restriction enzymes and PCR we analyzed the level of DNA methylation in the ovarian cancer cell line A2780 and compared it to the prostate cancer cell lines PC3 and C4-2. These experiments identified DNA methylation at the hx1 binding site in A2780 and PC3 cells but not in HBL100 cells and C4-2 cells. Most importantly, these preliminary studies reveal a complete correlation of DNA methylation and loss of CTCF binding; while hx1 in the prostate cell line C4-2 is both unmethylated and bound by CTCF, hx1 in the A2780 and PC3 cell lines is methylated and not bound by CTCF. These data further support our hypothesis that epigenetic mechanisms and loss of CTCF binding contribute to reprogramming of gene expression during disease progression.
To begin to address the potential role of CTCF binding and DNA methylation in deregulation of those genes identified by the Swisher lab, we scanned the genomic regions harboring the candidate genes for known CTCF binding sites. Importantly, the majority of the candidate genes is associated with one or more CTCF sites in a sequence space of 100 kb surrounding candidate loci. For only six loci is the closest CTCF binding site located more than 100 kb away. The distribution of CTCF sites across the subset of premalignant signature genes is similar to the distribution found genome-wide: About one half of CTCF sites are located in intergenic regions, with an average distance of approximately 47 kb. About 20% CTCF sites are located at transcription start sites, and 34% are located within introns and exons. Three examples of loci with CTCF binding sites in the vicinity of the genes under study are shown in Figure 3 .
To obtain initial data on differential binding of CTCF at premalignant signature genes, we performed methylation-sensitive PCR on genomic DNA from several cancer cell lines including the ovarian cancer cell line OVCAR3. This analysis takes advantage of the methylation-sensitive restriction enzyme AciI that digests only unmethylated genomic regions, eliminating templates for subsequent PCR. Thus, while unmethylated regions yield no PCR product, methylated regions are protected from restriction digest and produce amplified DNA fragments. Using this approach, we investigated the methylation status at PAK3, JAG1, and LOC388798 gene loci. As shown in Figure 3 , the CTCF binding region in PAK3 is methylated in the ovarian cancer cell line OVCAR3 but is un-methylated in the prostate cell line LnCaP. In contrast, our analyses at the LOC388798 on chromosome 20 revealed that this region is unmethylated in all cell lines tested.
KEY RESEARCH ACCOMPLISHMENTS  Within the list of genes that constitute our premalignant signature for ovarian cancer, we identified genomic loci that contain potential target sites for CTCF binding and/or DNA methylation.  We generated proof-of-principle data that demonstrate the influence of cancer-specific DNA methylation patterns with loss of CTCF binding at the HOX loci.  We provided initial evidence for antagonistic action of DNA methylation and CTCF binding at several loci in our premalignant signature. These results suggest that an extensive survey of epigenetic changes at ovarian cancer related genes will yield important results.
CONCLUSIONS
Our analyses have identified a premalignant expression signature which potentially reflects early steps in ovarian carcinogenesis. While genes differentially expressed in BRCA1 normal fallopian tube epithelia and BRCA1 ovarian carcinoma were identified in the Swisher lab, we have further established the proof-ofprinciple that demonstrates the role of DNA methylation of CTCF binding sites in cancer tissues. Importantly, we already gathered evidence that at least some of the genes that are part of the premalignant signature are differentially methylated in ovarian cancer cell lines. These data strongly encourage us to pursue an extensive survey of DNA methylation and CTCF binding in laser-captured tissues, as was proposed in our application. Thus, we have begun to isolate and pool samples for laser-capture microscopy. In the coming year, we will perform extensive mapping of DNA methylation to determine epigenetic changes that affect the normal expression of signature genes in ovarian cancer. . Genomic DNA digested with either AciI or EcoRV was amplified with primers specific for a CTCF binding region at LOC388796 (chr20). Absence of PCR product using genomic DNA digested by AciI indicates absence of methylation in all cell lines.
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